[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507999":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":25,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"first-line scheme + compound kushen injection","EXPERIMENTAL","Compound Kushen injection+first-line regimen (FOLFOX\u002FFOLFIRI\u002FCAPEOX± Cetuximab\u002Fbevacizumab)+",[13],"Drug: first-line scheme+compound kushen injection",{"label":15,"type":6,"description":16,"interventionNames":17},"first-line scheme","first-line regimen (FOLFOX\u002FFOLFIRI\u002FCAPEOX± Cetuximab\u002Fbevacizumab)",[18],"Drug: palliative care group first-line scheme",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","first-line scheme+compound kushen injection","FOLFOX\u002FFOLFIRI\u002FCAPEOX± Cetuximab\u002Fbevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"palliative care group first-line scheme","FOLFOX\u002FFOLFIRI\u002FCAPEOX± Cetuximab\u002Fbevacizumab",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"jie Li","CONTACT","88001711","qfm2020jieli@yeah.net",[37],{"facility":38,"status":39,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Guang 'anmen Hospital, China Academy of Chinese Medical Sciences","RECRUITING","Beijing","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":33,"phone":25,"phoneExt":25,"email":25},"Jie Li",{"type":53,"investigatorFullName":51,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Vice President","100507999","phase-4-survival-benefit-of-compound-kushen-injection-in-the-treatment-of-advanced-colorectal-cancer-100507999",false,"NCT05894694","Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer","Survival Benefit of Compound Kushen Injection in Treatment of Advanced Colorectal Cancer Based on Real World Registration Platform","Inclusion Criteria:\n\n① Patients with advanced CRC confirmed by pathology or cytology and receiving first-line therapy;② Aged ≥ 18 years old, male or female;③ ECOG score 0-2 points;④ Expected survival ≥ 3 months;⑤ According to RECIST1.1 criteria, at least one detectable lesion;⑥ Voluntarily join the study, sign informed consent, compliance with good cooperation with follow-up.\n\nExclusion Criteria:\n\n* Combined with other malignant primary tumors;\n\n  * Immunohistochemistry\u002Fpolymerase chain reaction\u002Fsecond-generation sequencing results suggest MSI-H\u002FdMMR patients;\n\n    * Patients with recurrence and metastasis within 6 months after radical tumor surgery;\n\n      * Patients who have previously or are undergoing cancer immunotherapy ; Patients undergoing radiation therapy;\n\n        * Pregnant or lactating women; women of childbearing age and their spouses can not take effective contraceptive measures during and within 6 months after the end of clinical study; ⑥ Psychiatric patients; ⑦ Patients with severe, uncontrolled organic disease or infection, such as decompensated heart, lung, kidney failure caused by intolerance to chemotherapy; ⑧ Patients who have received clinical trials of small molecule drugs within 28 days or received clinical trials of large molecule drugs within 3 months; ⑨ Patients who are known to be allergic to or intolerant of study drugs.","ALL","18 Years",{"count":65,"type":66},320,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.",[72],"Advanced Colorectal Carcinoma",[74,75],"Compound kushen Injection","Traditional Chinese medicine","2024-12-21",{"date":78,"type":79},"2024-12-27","ACTUAL",{"date":81,"type":79},"2023-09-27",{"date":83,"type":66},"2025-12-31",{"name":5,"class":6},1]